Voyager Therapeutics (VYGR) EBIAT (2016 - 2025)
Voyager Therapeutics' EBIAT history spans 11 years, with the latest figure at -$27.4 million for Q4 2025.
- For Q4 2025, EBIAT rose 20.47% year-over-year to -$27.4 million; the TTM value through Dec 2025 reached -$119.7 million, down 84.18%, while the annual FY2025 figure was -$119.7 million, 84.18% down from the prior year.
- EBIAT for Q4 2025 was -$27.4 million at Voyager Therapeutics, up from -$27.9 million in the prior quarter.
- Across five years, EBIAT topped out at $124.0 million in Q1 2023 and bottomed at -$34.5 million in Q4 2024.
- The 5-year median for EBIAT is -$21.9 million (2021), against an average of -$8.5 million.
- The largest annual shift saw EBIAT tumbled 513.84% in 2022 before it skyrocketed 681.85% in 2023.
- A 5-year view of EBIAT shows it stood at $5.7 million in 2021, then crashed by 513.84% to -$23.6 million in 2022, then skyrocketed by 338.7% to $56.4 million in 2023, then plummeted by 161.15% to -$34.5 million in 2024, then increased by 20.47% to -$27.4 million in 2025.
- Per Business Quant, the three most recent readings for VYGR's EBIAT are -$27.4 million (Q4 2025), -$27.9 million (Q3 2025), and -$33.4 million (Q2 2025).